GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » E10

Gilead Sciences (BUE:GILD) E10 : ARS1,613.13 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was ARS411.540. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS1,613.13 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Gilead Sciences's average E10 Growth Rate was 6.80% per year. During the past 3 years, the average E10 Growth Rate was 9.50% per year. During the past 5 years, the average E10 Growth Rate was 6.70% per year. During the past 10 years, the average E10 Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was 4.50% per year. And the median was 31.65% per year.

As of today (2024-04-27), Gilead Sciences's current stock price is ARS17771.50. Gilead Sciences's E10 for the quarter that ended in Dec. 2023 was ARS1,613.13. Gilead Sciences's Shiller PE Ratio of today is 11.02.

During the past 13 years, the highest Shiller PE Ratio of Gilead Sciences was 77.37. The lowest was 9.90. And the median was 14.99.


Gilead Sciences E10 Historical Data

The historical data trend for Gilead Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences E10 Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 176.60 288.93 521.70 1,613.13

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 521.70 642.40 821.65 1,360.65 1,613.13

Competitive Comparison of Gilead Sciences's E10

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.



Gilead Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=411.54/129.4194*129.4194
=411.540

Current CPI (Dec. 2023) = 129.4194.

Gilead Sciences Quarterly Data

per share eps CPI Adj_EPS
201403 10.546 99.695 13.690
201406 17.875 100.560 23.005
201409 14.060 100.428 18.119
201412 18.641 99.070 24.352
201503 24.342 99.621 31.623
201506 26.533 100.684 34.106
201509 28.771 100.392 37.090
201512 41.159 99.792 53.379
201603 36.948 100.470 47.594
201606 36.068 101.688 45.904
201609 37.143 101.861 47.192
201612 37.095 101.863 47.130
201703 31.605 102.862 39.765
201706 38.417 103.349 48.108
201709 36.098 104.136 44.862
201712 -56.521 104.011 -70.328
201803 23.574 105.290 28.977
201806 34.667 106.317 42.200
201809 58.878 106.507 71.544
201812 0.087 105.998 0.106
201903 60.199 107.251 72.642
201906 65.678 108.070 78.653
201909 -51.452 108.329 -61.469
201912 126.720 108.420 151.264
202003 75.725 108.902 89.992
202006 -182.104 108.767 -216.681
202009 21.530 109.815 25.374
202012 100.097 109.897 117.879
202103 123.410 111.754 142.917
202106 114.623 114.631 129.410
202109 200.449 115.734 224.151
202112 30.297 117.630 33.334
202203 2.147 121.301 2.291
202206 109.500 125.017 113.356
202209 197.309 125.227 203.915
202212 217.945 125.222 225.251
202303 158.040 127.348 160.611
202306 199.200 128.729 200.269
202309 605.414 129.860 603.362
202312 411.540 129.419 411.540

Add all the adjusted EPS together and divide 10 will get our e10.


Gilead Sciences  (BUE:GILD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=17771.50/1613.13
=11.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 77.37. The lowest was 9.90. And the median was 14.99.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gilead Sciences E10 Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.